DE eng

Search in the Catalogues and Directories

Hits 1 – 5 of 5

1
Review of Autism Profiles and Response to Sertraline in Fragile X Syndrome-Associated Autism vs. Non-syndromic Autism; Next Steps for Targeted Treatment.
Abstract: Given significant genetic, molecular, and phenotypic overlaps, researchers have begun to investigate whether targeted treatments for Fragile X Syndrome (FXS) could also be beneficial for patients with Autism Spectrum Disorder (ASD). For example, low-dose sertraline, an SSRI, was used in two recent controlled trials in children with FXS and ASD. The first trial recruited 52 children with FXS, 32 of which were also diagnosed with ASD; the second trial recruited 58 children with non-syndromic ASD. One focus of the present study is to compare the response to sertraline between the FXS-associated ASD and non-syndromic ASD groups. Another focus is to compare baseline ASD-related characteristics between the groups and review these differences within the context of recent literature comparing these populations. Our comparison showed more severe ASD profiles in children with non-syndromic ASD vs. FXS-associated ASD. Regarding response to sertraline, the FXS-ASD group displayed significant improvements in language development, while the non-syndromic group did not show any significant improvements. One possible explanation for this differential response is the distinct anxiety profiles that are seen in these two groups. The heightened anxiety phenotype seen in those with FXS-ASD may have led to a greater relief of anxiety symptoms with sertraline compared to those with non-syndromic ASD; this, in turn, could have led to measurably greater developmental gains. Further research is required to solidify this connection between anxiety relief and developmental gains in these populations.
Keyword: anxiety; Autism spectrum disorder; Clinical Sciences; Fragile X Syndrome; Neurosciences; Psychology; sertraline; targeted treatment
URL: https://escholarship.org/uc/item/9v44c8gr
BASE
Hide details
2
Molecular Biomarkers Predictive of Sertraline Treatment Response in Young Children With Autism Spectrum Disorder.
Alolaby, Reem Rafik; Jiraanont, Poonnada; Durbin-Johnson, Blythe. - : eScholarship, University of California, 2020
BASE
Show details
3
Molecular Biomarkers Predictive of Sertraline Treatment Response in Young Children With Autism Spectrum Disorder.
Alolaby, Reem Rafik; Jiraanont, Poonnada; Durbin-Johnson, Blythe. - : eScholarship, University of California, 2020
BASE
Show details
4
A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder.
Potter, Laura A; Scholze, Danielle A; Biag, Hazel Maridith B. - : eScholarship, University of California, 2019
BASE
Show details
5
A Randomized Controlled Trial of Sertraline in Young Children With Autism Spectrum Disorder.
Potter, Laura A; Scholze, Danielle A; Biag, Hazel Maridith B. - : eScholarship, University of California, 2019
BASE
Show details

Catalogues
0
0
0
0
0
0
0
Bibliographies
0
0
0
0
0
0
0
0
0
Linked Open Data catalogues
0
Online resources
0
0
0
0
Open access documents
5
0
0
0
0
© 2013 - 2024 Lin|gu|is|tik | Imprint | Privacy Policy | Datenschutzeinstellungen ändern